TipRanks
TG Therapeutics (DE:NKB2)
FRANKFURT:NKB2
Germany Market
NKB2
TG Therapeutics
RESEARCH TOOLSreports

TG Therapeutics (NKB2) Ratios

3 Followers

TG Therapeutics Ratios

DE:NKB2's free cash flow for Q2 2026 was $0.83. For the 2026 fiscal year, DE:NKB2's free cash flow was decreased by $ and operating cash flow was $0.09. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 4.27 4.10 6.25 5.92 3.16
Quick Ratio
 3.72 3.29 5.03 5.18 3.16
Cash Ratio
 1.80 0.51 1.98 1.73 1.92
Solvency Ratio
 0.43 1.08 0.07 0.08 -1.65
Operating Cash Flow Ratio
 >-0.01 -0.16 -0.45 -0.58 -3.31
Short-Term Operating Cash Flow Coverage
 0.00 -23.73 0.00 0.00 0.00
Net Current Asset Value
$ 110.14M$ 215.53M$ 211.03M$ 148.86M$ 33.29M
Leverage Ratios
Debt-to-Assets Ratio
 0.46 0.25 0.44 0.34 0.43
Debt-to-Equity Ratio
 1.25 0.40 1.14 0.69 1.42
Debt-to-Capital Ratio
 0.56 0.29 0.53 0.41 0.59
Long-Term Debt-to-Capital Ratio
 0.55 0.28 0.52 0.38 0.55
Financial Leverage Ratio
 2.71 1.64 2.60 2.05 3.30
Debt Service Coverage Ratio
 12.64 17.07 1.98 2.04 -20.91
Interest Coverage Ratio
 3.64 4.61 1.75 1.64 -21.42
Debt to Market Cap
 0.09 0.06 0.06 0.04 0.04
Interest Debt Per Share
 5.59 1.99 1.91 0.87 0.69
Net Debt to EBITDA
 2.03 1.35 1.48 0.68 0.09
Profitability Margins
Gross Profit Margin
82.36%83.66%88.30%93.95%90.48%
EBIT Margin
16.75%21.76%15.08%10.99%-7670.41%
EBITDA Margin
16.78%21.80%15.17%11.17%-7651.92%
Operating Profit Margin
17.05%20.01%12.74%8.83%-7838.99%
Pretax Profit Margin
12.71%17.43%7.78%5.59%-8036.34%
Net Profit Margin
55.22%72.56%7.11%5.42%-8036.34%
Continuous Operations Profit Margin
55.22%72.56%7.11%5.42%-8036.34%
Net Income Per EBT
434.54%416.41%91.36%97.01%100.00%
EBT Per EBIT
74.53%87.08%61.04%63.31%102.52%
Return on Assets (ROA)
26.93%42.06%4.05%3.84%-115.62%
Return on Equity (ROE)
72.30%69.01%10.52%7.90%-382.02%
Return on Capital Employed (ROCE)
9.94%13.56%8.61%7.48%-155.53%
Return on Invested Capital (ROIC)
9.93%13.54%7.85%7.22%-153.80%
Return on Tangible Assets
26.93%42.06%4.05%3.85%-116.10%
Earnings Yield
5.48%10.39%0.53%0.52%-13.97%
Efficiency Ratios
Receivables Turnover
 1.99 2.02 2.55 4.57 0.00
Payables Turnover
 0.66 0.94 0.00 0.00 0.00
Inventory Turnover
 0.95 0.80 0.35 0.35 0.00
Fixed Asset Turnover
 112.85 98.17 46.01 29.03 0.26
Asset Turnover
 0.49 0.58 0.57 0.71 0.01
Working Capital Turnover Ratio
 0.90 1.29 0.89 1.23 0.01
Cash Conversion Cycle
 13.20 246.53 1.19K 1.11K 0.00
Days of Sales Outstanding
 183.32 181.01 143.32 79.81 0.00
Days of Inventory Outstanding
 383.05 455.14 1.05K 1.03K 0.00
Days of Payables Outstanding
 553.17 389.62 0.00 0.00 0.00
Operating Cycle
 566.37 636.15 1.19K 1.11K 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
 >-0.01 -0.17 -0.28 -0.22 -1.30
Free Cash Flow Per Share
 >-0.01 -0.17 -0.28 -0.22 -1.30
CapEx Per Share
 <0.01 <0.01 <0.01 0.00 <0.01
Free Cash Flow to Operating Cash Flow
 31.11 1.01 1.00 1.00 1.00
Dividend Paid and CapEx Coverage Ratio
 -0.03 -115.76 -900.38 0.00 -12.58K
Capital Expenditure Coverage Ratio
 -0.03 -115.76 -900.38 0.00 -12.58K
Operating Cash Flow Coverage Ratio
 >-0.01 -0.10 -0.16 -0.28 -2.12
Operating Cash Flow to Sales Ratio
 >-0.01 -0.04 -0.12 -0.13 -63.26
Free Cash Flow Yield
>-0.01%-0.58%-0.93%-1.30%-11.00%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 18.68 9.62 188.13 191.33 -7.16
Price-to-Sales (P/S) Ratio
 10.89 6.98 13.29 10.38 575.19
Price-to-Book (P/B) Ratio
 13.35 6.64 19.67 15.11 27.34
Price-to-Free Cash Flow (P/FCF) Ratio
 -15.55K -172.18 -107.84 -77.18 -9.09
Price-to-Operating Cash Flow Ratio
 -447.92K -173.67 -107.96 -77.18 -9.09
Price-to-Earnings Growth (PEG) Ratio
 0.03 <0.01 2.38 -1.80 0.16
Price-to-Fair Value
 13.35 6.64 19.67 15.11 27.34
Enterprise Value Multiple
 66.91 33.37 89.13 93.58 -7.43
Enterprise Value
 8.98B 4.48B 4.45B 2.44B 1.58B
EV to EBITDA
 66.91 33.37 89.13 93.58 -7.43
EV to Sales
 11.23 7.28 13.52 10.45 568.28
EV to Free Cash Flow
 -16.03K -179.45 -109.66 -77.75 -8.98
EV to Operating Cash Flow
 -498.76K -181.00 -109.78 -77.75 -8.98
Tangible Book Value Per Share
 4.26 4.49 1.53 1.13 0.43
Shareholders’ Equity Per Share
 4.26 4.49 1.53 1.13 0.43
Tax and Other Ratios
Effective Tax Rate
 -3.35 -3.16 0.09 0.03 0.00
Revenue Per Share
 5.64 4.27 2.26 1.65 0.02
Net Income Per Share
 3.11 3.10 0.16 0.09 -1.65
Tax Burden
 4.35 4.16 0.91 0.97 1.00
Interest Burden
 0.76 0.80 0.52 0.51 1.05
Research & Development to Revenue
 0.28 0.26 0.29 0.33 45.01
SG&A to Revenue
 0.37 0.38 0.47 0.53 34.29
Stock-Based Compensation to Revenue
 0.13 0.10 0.13 0.16 6.89
Income Quality
 >-0.01 -0.06 -1.73 -2.48 0.89
Currency in USD